NVCR News and Press, NovoCure Limited From 10/04/21

Final data collection is expected in the first half of 2022 SHANGHAI and St. Helier, JERSEY, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, and Novocure (NASDAQ: NVCR), a global oncology com...

Novocure (NASDAQ: NVCR) announced today that it will report financial results for the third quarter 2021 on Thursday, October 28, 2021, before the U.S. financial markets open. Novocure’s management will host a conference call and webcast to discuss its financial results for the t...

Novocure (NASDAQ: NVCR) today announced it has entered into a clinical trial collaboration agreement with Roche (SIX: RO. ROG; OTCQX: RHHBY), to develop Tumor Treating Fields (TTFields) together with Roche’s anti-PD-L1 therapy, atezolizumab, in metastatic pancreatic ductal adenoc...

NovoCure has developed and is commercializing a therapy for fast-growing and aggressive brain tumor using TTFields. Its product has reached maturity phase in core active markets, with an expansion in new geographies on the cards. The healthcare equipment play is investing heavily ...

Novocure (NASDAQ: NVCR) is the producer of a cancer-fighting wearable device called Optune. Its tumor-treating technology uses low-power electrical fields to interfere with a cancer cell's ability to multiply. The stock skyrocketed 40% in a single day back in April on positive n...

NovoTTF-200T is a Tumor Treating Fields delivery system intended for use together with atezolizumab and bevacizumab for the treatment of patients with advanced liver cancer Novocure (NASDAQ: NVCR) today announced the United States Food and Drug Administration (FDA) has grant...

Novocure (NASDAQ: NVCR) announced today that Ashley Cordova, Chief Financial Officer, and Pritesh Shah, Chief Commercial Officer, will participate in the 2021 Wells Fargo Virtual Healthcare Conference on September 10, 2021. Ms. Cordova and Mr. Shah will take part in a fireside chat at 1...

Novocure (NASDAQ: NVCR) today announced that William (Bill) Burke has been promoted to Chief Human Resources Officer, effective September 1, 2021. This appointment reflects the importance of Novocure’s team members to our anticipated growth. Mr. Burke joined Novocure in 2014 ...

On Aug. 16, institutional investment managers with more than $100 million AUM had to disclose their positions at the end of Q2 2021. I curated a list of some of the best-performing hedge funds and looked into their holdings at the end of June 2021. Several common themes appear whe...

Novocure (NASDAQ: NVCR) disappointed investors with its second-quarter results announced on July 29. However, the company could have better news on the way. In this Motley Fool Live video recorded on Aug. 4 , Motley Fool contributors Keith Speights and Brian Orelli discuss w...